Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Overview of attention for article published in New England Journal of Medicine, March 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 15 news outlets
blogs: 12 blogs
policy: 3 policy sources
twitter: 52 X users
patent: 32 patents
facebook: 11 Facebook pages

wikipedia: 4 Wikipedia pages
googleplus: 1 Google+ user
reddit: 3 Redditors
f1000: 1 research highlight platform
guideline: 17 clinical guideline sources

Readers on

mendeley: 880 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 24 news stories from 15 outlets.

FOURIER: Evolocumab follow-up shows no cognitive adverse effects

Pediatric News , 09 Jun 2026

Treatment with a PCSK9 inhibitor, as well as achieving dramatically lowered cholesterol levels, did not mess with patients…

Adverse Event Data Mining Finds Few Ocular Side Effects From PCSK9 Inhibitors

HCP Live, 24 Aug 2022

Pharmacovigilance studies sifting through FDA adverse event reports confirm ocular side effects from PCSK9 inhibitors are…

FOURIER: Evolocumab Follow-up Shows No Cognitive Adverse Effects

Medscape, 05 May 2020

Treatment with a PCSK9 inhibitor, as well as achieving dramatically lowered cholesterol levels, did not mess with patients…

FOURIER: Evolocumab follow-up shows no cognitive adverse effects

Pediatric News , 04 May 2020

Treatment with a PCSK9 inhibitor, as well as achieving dramatically lowered cholesterol levels, did not mess with patients…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 20 additional news stories.